In Search of the Holy Grail for the Treatment of Neurodegenerative Disorders: Has a Simple Cation Been Overlooked?
- 1 July 2007
- journal article
- editorial
- Published by Elsevier in Biological Psychiatry
- Vol. 62 (1) , 4-6
- https://doi.org/10.1016/j.biopsych.2007.04.008
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Mood Stabilizers Target Cellular Plasticity and Resilience Cascades: Implications for the Development of Novel TherapeuticsMolecular Neurobiology, 2005
- GSK-3α regulates production of Alzheimer's disease amyloid-β peptidesNature, 2003
- From chemical to drug: neurodegeneration drug screening and the ethics of clinical trialsNature Neuroscience, 2002
- Lithium and valproic acid: parallels and contrasts in diverse signaling contextsPharmacology & Therapeutics, 2002
- Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brainPsychopharmacology, 2001
- The multifaceted roles of glycogen synthase kinase 3β in cellular signalingPublished by Elsevier ,2001
- Long Term Lithium Treatment Suppresses p53 and Bax Expression but Increases Bcl-2 ExpressionJournal of Biological Chemistry, 1999
- The Mood‐Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl‐2 in the CNSJournal of Neurochemistry, 1999
- Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3Journal of Biological Chemistry, 1997
- A molecular mechanism for the effect of lithium on development.Proceedings of the National Academy of Sciences, 1996